ABSTRACT
Following the waning severity of COVID-19 due to vaccination and the development of immunity, the current variants of SARS-CoV-2 often lead to mild upper respiratory tract infections (MURTIs), suggesting it is an appropriate time to review the pathogenesis and treatment of such illnesses. The present article reviews the diverse causes of MURTIs and the mechanisms leading to symptomatic illness. Different symptoms of MURTIs develop in a staggered manner and require targeted symptomatic treatment. A wide variety of remedies for home treatment is available, including over-the-counter drugs and plant-derived substances. Recent pharmacological research has increased the understanding of molecular effects, and clinical studies have shown the efficacy of certain herbal remedies. However, the use of subjective endpoints in these clinical studies may suggest limited validity of the results. In this position paper, the importance of patient-centric outcomes, including a subjective perception of improved well-being, is emphasized. A best practice approach for the management of MURTIs, in which pharmacists and physicians create an improved multi-professional healthcare setting and provide healthcare education to patients, is proposed. Pharmacists act as first-line consultants and provide patients with remedies, considering the individual patient's preferences towards chemical or plant-derived drugs and providing advice for self-monitoring. Physicians act as second-line consultants if symptoms worsen and subsequently initiate appropriate therapies. In conclusion, general awareness of MURTIs should be increased amongst medical professionals and patients, thus improving their management.
ABSTRACT
OBJETIVO: Determinar la prevalencia de RCV entre las personas que acuden a las farmacias de la provincia de Toledo. Determinar la capacidad de las farmacias para valorar el RCV. MATERIAL Y MÉTODO: Estudio observacional transversal poblacional de campo en el que se va a estudiar el RCV de la población de la Provincia de Toledo que cumpla con los criterios de inclusión. Entre 40 y 65 años. Dar el consentimiento. Estado cognitivo no deteriorado. Estar diagnosticado y / o en tratamiento de ninguna o solamente de una de las siguientes patologías: HTA, DP o DMT2. RESULTADOS: Las farmacias detectaron FRCV en más de la mitad de los pacientes. En la valoración del RCV un 3,9% (15) presentaba RCV alto o muy alto y un 48,3% (186) con RCV moderado. Pacientes con diagnóstico previo de alguna de las patologías crónicas a estudio presentaron un incumplimiento del objetivo terapéutico y/o niveles alterados de valores diagnósticos de patologías de las que no habían sido diagnosticados, este es el caso del 61,5% (8) de pacientesDMT2, el 11,7% (9) de pacientes HTA y el 8,8% (5) de pacientes DP que presentan indicadores de riesgo elevado. CONCLUSIÓN: Concluimos la capacidad real de las farmacias para detectar FRCV entre las personas que acuden a ellas y de evaluar su RCV con fiabilidad. Obtenemos correlación con los resultados con los de la OMS en cuanto al fracaso terapéutico y demostramos el mal control de la población en general sobre patologías relacionadas con el RCV
OBJETIVE: Determine the prevalence of CVR among people who visit pharmacies in the region of Toledo. Determine the capacity of pharmacies to assess CVR. METHODS: It is carried out an observational cross-sectional study in which the CVR of the population of the region of Toledo that meets the inclusion criteria will be studied: Between 40 and 65 years old, with consent, cognitive state not impaired, be diagnosed and / or under treatment of any or only one of the following pathologies: HTA, DP or DMT2. RESULTS: Pharmacies detected CVRF in more than half of the patients. In the CVR assessment, 3.9% (15) had high or very high RCV and 48.3% (183) had moderate CVR. Patients with a previous diagnosis of any of the chronic pathologies under study had a noncompliance with the therapeutic objective and / or altered levels of diagnostic values of pathologies that had not been diagnosed. This is the case of 61.5% (8) of patients on DMT2, 11.7% (9) of HTA patients and 8.8% (5) of DP patients who present high risk indicators. CONCLUSION: We conclude pharmacies have a real capacity to detect CVRF among people who come to them and they can also evaluate their CVR with reliability. We obtained correlation in the results with those of the WHO regarding the therapeutic failure and we proved the bad control of the population in general on pathologies related to the CVR
